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Toxin structure: Part of a hole?
Hagan Bayley
The structure of the monomeric form of perfringolysin O
solved by X-ray crystallography has been used to model
the very large transmembrane pore formed when this
bacterial protein toxin assembles in cholesterol-
containing membranes. The structure is a notable
advance, but it may not provide the whole story.
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Proteins that form sizeable holes in membranes (as opposed
to narrow channels) are ubiquitous in nature and include
bacterial toxins, bacterial and mitochondrial porins, proteins
involved in host-cell penetration and lysis by bacteriophage,
the translocons required for protein secretion and mem-
brane protein assembly, gap junctions, nuclear pores, pore-
forming proteins of the immune system, and more.
Three-dimensional structures at atomic resolution have
been obtained by X-ray crystallography for several pore-
forming toxins that allow the passage of small molecules of
around 1000 Da (reviewed in [1]). With the notable excep-
tion of porins, this is all the structural information we have
about pore-forming proteins. Conspicuously lacking has
been the structure of a protein capable of forming very large
pores that can, for example, allow the passage of folded pro-
teins. Hence, the recently solved structure of a monomeric
form of perfringolysin O (PFO, theta toxin) from Clostrid-
ium perfringens is a major step forward [2].
A family of cytolysins
PFO is a member of the expanding family of cytolysins
epitomized by streptolysin O (SLO) [3,4]. In most cases,
these proteins are secreted as monomers of 50–80 kDa.
Amino-terminal extensions of various lengths account for
differences in mass and the remaining 450 carboxy-termi-
nal residues are 40–70% identical. The biological activity
of the SLO family depends on the presence of membrane
cholesterol, and is inhibited by nanomolar concentrations
of free cholesterol and closely related sterols [3].
Proteins of the SLO family oligomerize to form transmem-
brane pores more than 30 nm in external diameter, con-
taining 40–80 monomers per pore, which appear as
spectacular, large, circularized structures by electron
microscopy (Figure 1) [5]. Individual members of the
family contain rings with a variable number of subunits
(for example, 40–50 for pneumolysin (PLY) [4]). In this
regard, these structures, with large radii of curvature, fall
between small pores, which have fixed numbers of sub-
units, and linear protein polymers of variable length. The
pores contain no additional polypeptides and have no
receptor other than cholesterol. The circular structures are
often incomplete and ‘banana-like’ structures or arcs are
seen by electron microscopy [5]. Like circular pores, these
arcs also cause the target cells to leak, as suggested by
osmotic protection experiments (M. Palmer and S.
Bhakdi, personal communication) and planar bilayer
recordings [6].
SLO and its relatives are virulence factors. Their mode of
action is now viewed as being more subtle than the
‘Rambo-style’ blowing of holes in cell membranes. Sub-
lytic concentrations of the toxins are involved in numerous
physiological changes associated with infection, including
the release of potent protein factors, such as tumor necro-
sis factor α and interleukin-1β [4,7]. These events are pre-
sumably initiated by the stimulation of intracellular signal
transduction pathways by Ca2+ influx, for example. In
addition, the activation of phospholipases, by an unknown
Figure 1
Electron micrographs of streptolysin O [5].
Purified SLO complexes were incorporated
into cholesterol-free liposomes and negatively
stained with sodium silicotungstate. Complete
rings (a) and an arc (b) are displayed. SLO
projects about 5 nm from the outer surface of
the bilayer, as seen in (c) as profile views
(labelled with p). As the total height of the
structure is about 9.5 nm, there is probably
little protein projecting from the inner surface
of the bilayer. The scale bar corresponds to
100 nm.
mechanism, can catalyze the release of lipid-derived sig-
naling molecules [4,7]. Proteins of the SLO family are also
able to activate the classical complement pathway in the
absence [4] or the presence of anti-toxin antibodies [8].
Complement fixation may serve to divert host defences
from the bacterium or to induce attack by complement on
host cell membranes [4,8].
Structure of perfringolysin O
The structure of monomeric PFO has been determined to
2.7 Å resolution by X-ray diffraction by Jamie Rossjohn
and colleagues in Michael Parker’s laboratory [2]. The
molecule is elongated (11.5 × 3 × 5.5 nm) and comprises
four domains that are rich in β-sheet structure (Figure 2).
Perhaps the only direct clue from the structure about pore
formation is the location of a tryptophan-rich sequence at
one end of the rod in the carboxy-terminal domain 4
(Figure 2). This sequence, ECTGLAWEWWR (single-
letter amino-acid code), is highly conserved in the SLO
family. Mutagenesis suggests that the integrity of the
sequence is important for activity: in many point mutants,
the binding and oligomerization properties are retained,
but activity is lost (Figure 2). By contrast, in other mutants
and after chemical modification of the cysteine residue,
the protein no longer binds to membranes. Additional
mutations that weaken the affinity of SLO family
members for membranes lie elsewhere in domain 4 near
the carboxyl terminus (Figure 2). Much of the mutagene-
sis data [3,4,9] is unsatisfying, however, because binding
to free cholesterol and binding to membranes should be
distinguished, studies of oligomerization are not or cannot
be performed quantitatively and cell lysis is not a simple
linear process like a typical enzyme assay. Nevertheless,
because all the mutations that affect binding fall in the
structurally autonomous domain 4, the data on balance
suggest that cholesterol binds somewhere in this domain.
In support of this view, proteolytic fragments of PFO
and PLY that contain predominantly domain 4 bind to
cholesterol and to cholesterol-containing membranes.
These fragments form arcs but are nonlytic and prevent
lysis by intact PFO, presumably by blocking intersubunit
interactions [10].
Despite the complexities of the binding data, Rossjohn
and colleagues [2] envision a binding site for cholesterol in
the tryptophan-rich region of domain 4, remodeling the
polypeptide before docking the steroid. They suggest that
the tryptophan-rich motif and the cholesterol molecule
combine to form a ‘dagger’ capable of membrane penetra-
tion. In support of this proposal, the fluorescence of tryp-
tophans in domain 4 of PFO is quenched after assembly
on liposomes containing brominated lipids [10]. Moreover,
aromatic residues in transmembrane proteins often cluster
near the interface of the membrane and the aqueous
phase [1,11].
Another striking feature of domain 4 is the fold, which
resembles transthyretin, a protein that forms amyloid-like
polymers with intermolecular β sheets [12] that may be
required for the assembly of PFO (see below), as well as
other toxin pores [1,13]. A region of the protein that has
been implicated in complement activation is also in
domain 4 [4], but distant from the tryptophan-rich motif
(Figure 2). Domain 1, as well as domain 4, has previously
been implicated in oligomerization. Notably, a monoclonal
antibody that binds here, close to the interface with
domain 3 (Figure 2), allows membrane binding but pre-
vents oligomerization [14].
A model for membrane insertion
Based on their structure of the monomer and electron
micrographs from previous studies, Rossjohn and col-
leagues [2] have devised a model for membrane insertion
by PFO (Figure 3a), which is likely to be both influential
and controversial. In Rossjohn’s scheme [2], individual
subunits descend onto a lipid bilayer where they find cho-
lesterol-rich patches and then oligomerize. Cholesterol
bound in the oligomers causes a rearrangement of the
R764 Current Biology, Vol 7 No 12
Figure 2
Ribbon diagram of the PFO monomer [2] showing the major sites
discussed in the text. Many simplifications have been made and the
data are compiled from results with PFO, SLO, PLY and listeriolysin.
The residue numbering corresponds to that of PFO. A major anti-SLO
binding site involved in complement activation has been mapped to
domain 1 (S. Bhakdi, personal communication). Chemical modification
of the SLO mutant T250C (PFO position 180) yields a protein that
caps growing oligomers (M. Palmer and S. Bhakdi, personal
communication).
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tryptophan-rich motif to form the hydrophobic dagger
that penetrates the bilayer. Important features of the
model for membrane insertion include: oligomerization
prior to membrane penetration; strong interactions
between domains 1 well above the membrane surface;
bending at the interface between domains 1 and 3 to form
a continuous intramolecular β sheet; domain 4 as the
exclusive membrane-penetrating domain; reorganization
of domain 4 to bind cholesterol; the presence of bound
cholesterol in the arcs and rings to protect a hydrophilic
face of domain 4 within the bilayer; and the formation of a
continuous intermolecular β sheet around the entire struc-
ture by one face of domain 4.
How good is the model?
There are arguments in favor of many aspects of the
model; for example, there are relatively modest changes in
secondary structure during assembly [10]. Other features
will be seen as questionable or unresolved, however, and
thereby present a valuable stimulus for further experi-
mentation. For instance, the shape of the proposed mem-
brane-inserted structure agrees fairly well with images
obtained by electron microscopy (references in [2]), but
does not withstand close scrutiny. From electron
microscopy, the total height of the structure is 9–10 nm,
with about 5 nm projecting above the bilayer surface. The
longest dimension in the crystal is 11.5 nm, which should
correspond to the height of the uninserted subunits.
According to the model, each subunit becomes elongated
upon insertion to about 14 nm, 8.5 nm of which projects
above the membrane surface, and this clearly conflicts
with the electron microscopy data. The periodicity at the
outer limit of the ring (2.4 nm) is, however, a reasonable fit
with the crystal structure (3 nm dimension). The width of
the ring is 4.8–7.5 nm, which corresponds roughly to the
5.5 nm dimension in the crystal. The variation in observed
width between different studies by electron microscopy
does not seem to correlate with the variable mass of the
amino-terminal domain in the SLO family.
Kinetic studies tell us that monomeric SLO binds
reversibly to membranes, dimer formation is rate limiting,
and elongation to arcs is relatively rapid, providing the
basis of an alternative model for assembly (Figure 3b)
[15]. Membrane leakage can be induced by small
oligomers ([6]; M. Palmer and S. Bhakdi, personal commu-
nication), which suggests that membrane penetration is an
early event. By contrast, the scheme of Rossjohn and col-
leagues indicates that extensive oligomerization occurs
before membrane penetration. Arcs cause larger leaks in
the membrane, which implies that the bilayer is grossly
disrupted in the vicinity of these structures. The Rossjohn
paper [2] makes no suggestions about how the boundary
of the lipid appears in the arcs and how the rearranged
bilayer would form an interface with the protein [5].
The Rossjohn model also suggests that cholesterol is inti-
mately associated with membrane-inserted PFO arcs and
rings. However, extensively delipidated SLO rings can be
reconstituted in cholesterol-free bilayers and appear per-
fectly accommodated [5], although it is not certain that
one remaining equivalent of tightly bound cholesterol
would have been detected in these studies. PLY
oligomers can form from highly concentrated solutions of
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Figure 3
Two models for the formation of arcs and
rings by the SLO family of toxins. (a) A model
based closely on that of Rossjohn and
colleagues [2]. PFO binds to the membrane
at a cholesterol-rich patch through domain 4
(cholesterol molecules are shown in green).
Oligomers then form on the membrane
surface. Finally, the oligomers insert into the
membrane to form an arc or ring in which a
cholesterol molecule is retained by domain 4
and protects a hydrophilic face of the protein
from the hydrocarbon core of the bilayer. The
ring projects about 8.5 nm from the bilayer
surface. (b) Model for assembly based on the
additional biochemical and biophysical studies
discussed in the text. The monomer binds to
the bilayer in a reversible step that requires
cholesterol and most probably involves
domain 4 directly. In a rate-determining step,
the monomers dimerize and segments of the
polypeptide including sequences in domain 3
insert into the bilayer. A role for cholesterol
beyond this step has not been proven and,
therefore, the cholesterol may be released as
shown. The dimer elongates by the addition of
additional membrane-bound monomers that
insert into the membrane as they enter the
complex. The membrane is breached by the
growing arcs. Finally, a large arc or ring is
formed that projects about 5 nm from the
membrane and does not require annular
cholesterol for structural stability. This slow
nucleation followed by rapid propagation is
similar to the way in which amyloid proteins
polymerize, except that, in the case of the
toxins, termination occurs upon circularization.
monomer in the absence of cholesterol, and these sterol-
free assemblies do not bind cholesterol (R. Gilbert, per-
sonal communication). Specifically, Rossjohn and
colleagues suggest that one of the faces of domain 4 that
enters the bilayer is polar and must, therefore, be shielded
by cholesterol, which seems unlikely given the physical
properties of this molecule — a C27 hydrocarbon with just
a single hydroxyl group, normally located in the head-
group region of the bilayer. Evidence for masking of a
hydrophilic site for membrane insertion has been obtained
for an activation domain of protein kinase Cδ, where
phorbol ester covers a polar groove on a predominantly
hydrophobic surface of the protein [16]. 
In further conflict with details of the model, scanning
mutagenesis and fluorescence emission experiments
suggest that at least part of domain 3 enters the lipid
bilayer [17]. In this approach, a dye such as acrylodan,
which shows a large blue shift in emission upon transfer
from a hydrophilic environment into a hydrophobic one, is
attached at single cysteines in a polypeptide: fluorescence
emission spectra are recorded before and after assembly
[18,19]. In the case of SLO, a relatively small number of
fluorescent mutants — 19 — have been published so far.
The studies suggest that residues 274 (204), 286 (216) and
403 (333) in domain 3 (PFO residue numbers in parenthe-
ses) are in contact with the lipid bilayer (Figure 2).
Resolving the matter
The Rossjohn model is a thought-provoking scheme quite
different from the assembly pathways proposed or sub-
stantiated for other pore-forming proteins. These path-
ways are largely based on the formation of transmembrane
helix bundles or β barrels with internally hydrogen-
bonded backbones and non-polar side chains in contact
with the hydrocarbon core of the bilayer. In this regard,
however, it is important to remember that α-hemolysin is
the only pore-forming toxin for which the structure of the
transmembrane region has actually been solved [1]. It
would therefore be wonderful to see the three-dimen-
sional structure of a PFO ring or an arc, but this is an
unlikely prospect, firstly because of the heterogeneity of
rings and arcs, and secondly because of the difficulty in
crystallizing large, water-filled objects, which would
present a minimum of protein contacts and a deformable
structure. The structure of a dimer formed by a wild-type
monomer and a mutant that caps the nucleated arc is a
more realistic endeavor. Nuclear magnetic resonance is
also problematic for such large molecules. Infra-red spec-
troscopy, circular dichroism, intrinsic fluorescence and
related techniques, in which the signal cannot be assigned
to specific residues without considerable effort, have also
been of little use in such situations, even where oriented
samples have been examined. Therefore, some ingenuity
will be required to construct viable structures by using
cryo-electron microscopy, scanning force microscopy and
model building, supported by additional biochemical data.
Approaches that yield information for the SLO family will
be applicable to other large pores, which include the
membrane-attack complex of complement, perforin,
holins (the phage lysis proteins) and nuclear pores.
Targeted chemical modification with spectroscopic probes
will continue to be useful for identifying the disposition of
residues in membrane proteins, such as residues that
contact the hydrocarbon core of the bilayer or line the
lumen of the transmembrane channel, or residues that are
involved in subunit contacts and conformational changes.
Electron paramagnetic resonance experiments in which
probes are attached to single cysteines [20] are a useful
alternative to the fluorescence approach. Difficulties may
arise with these approaches if membrane lipids, such as
cholesterol, bind tightly to sites on the toxin: for example,
the covalently attached probe might disrupt an important
interaction with the sterol. Furthermore, it may not always
be possible to assign secondary structure to membrane-
inserted sequences because the probe may perturb locally
flexible domains [18,19]. To identify residues that line
the lumen of the transmembrane channel in the arcs and
pores, variations of surface cysteine-labeling techniques
should prove useful [21]. These techniques are espe-
cially powerful when combined with functional measure-
ments, especially single-channel recording. However,
new bulky or highly charged probes will be needed to
alter significantly the conductances of the large pores of
the SLO family.
In the scanning mutagenesis and fluorescence approach, it
is perilous to omit even short stretches of residues (8–10
residues of a β sheet can span a bilayer) and schemes in
which entire proteins or at least entire domains are sub-
jected to single cysteine substitution at every position are
recommended. Furthermore, quenching nitroxyl or halo-
genated lipids should be used to confirm movement into
the bilayer, and water-soluble quenchers of various sizes
should be used to identify positions in the lumen of a
transmembrane channel [22]. The effort expended in a
comprehensive cysteine scan can be useful in other ways:
for example, intramolecular and intermolecular disulfides
can be used to clamp the polypeptide and might be useful
for testing the strong domain 1–domain 1 interaction pro-
posed for PFO [2]. 
There is also a pressing need for better identification of
the residues involved in binding cholesterol. First, it
should be recognized that the cholesterol dependence of
SLO and its relatives differs fundamentally from that of
eukaryotic membrane proteins such as rhodopsin, Ca2+-
ATPase and the nicotinic acetylcholine receptor. The
latter have an ill-defined number of relatively weak,
fairly non-specific cholesterol-binding sites, whereas the
toxins bind a few sterol molecules, perhaps one, rather
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specifically with an affinity of ~10–9 M [3]. Domain 4 is
by far the best candidate for the site, but there is no evi-
dence that the region around the conserved cysteine is
directly involved. Photoaffinity labeling is a possible
approach to examine a chemically unreactive binding
site. Alternatively, single cysteine mutants might be
screened for reactivity with alkylating derivatives of cho-
lesterol. In addition, the role of cholesterol at each stage
in assembly needs to be fully defined. Some would claim
that cholesterol partakes solely in the binding step
(Figure 3b), whereas the Rossjohn paper sees a role for
cholesterol throughout assembly and in stabilizing the
assembled arcs and pores (Figure 3a). Here, the use of
lipid derivatives that keep cholesterol on one side of the
bilayer or fix its orientation in the membrane might be
helpful [23]. Brominated sterols might also be used as
quenchers in conjunction with fluorescence experiments.
While studies of structure continue, it should not be for-
gotten that we need to know more about the steps in
assembly and their kinetics. Even the crudest outline of
an assembly pathway (Figure 3) raises several questions.
Which steps require cholesterol? If several steps require
cholesterol, is the same sterol molecule bound to the same
site on the toxin throughout assembly? Is the cholesterol
removed from its normal site in the membrane? At what
stage does membrane insertion occur? At what stage are
holes formed? What happens at the edges of the arcs? Is
arc growth unidirectional? Only when this information is
available can we fully exploit the new structure to get the
whole story.
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